Evidence for a Relationship between Plasma Immunoreactive Calcitonin and Bone Disease in chronic Renal Failure

In experimental animals a major effect of the administration of calcitonin (CT) is to inhibit bone resorption and this property has led to its use in man to suppress excessive bone turnover in Paget’s disease and other disorders (1–4). On the other hand, the role of endogenous CT in the pathogenesis of bone disease has remained unresolved. The present studies were designed to examine the relationships between plasma immunoreactive CT (iCT), parathyroid hormone (iPTH) and bone disease in chronic renal failure.